A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial.

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the ... were it will compete against Eli Lilly’s Olumiant. Sun Pharmaceuticals is acquiring Concert ...

In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis ...

A recent case-control study found a significant association in the prevalence of alopecia areata in patients diagnosed with celiac disease.

DelveInsight's Alopecia Areata Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire ...